Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2024 Feb 9;15:1376058. doi: 10.3389/fphar.2024.1376058

Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease

Weiwei Lin 1,2, Fatemeh Mousavi 1, Benjamin C Blum 1,2, Christian F Heckendorf 1,2, Jarrod Moore 1,2, Noah Lampl 1,2, Mark McComb 1,2, Sergei Kotelnikov 3, Wenqing Yin 4, Nabil Rabhi 2, Matthew D Layne 2, Dima Kozakov 3, Vipul C Chitalia 4,5,6, Andrew Emili 1,2,7,*
PMCID: PMC10884821  PMID: 38405670

In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.”

The correct Funding statement appears below.

“This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES